Zentalis Pharmaceuticals’ $200.2 Million Common Stock Offering

Latham & Watkins represented Zentalis Pharmaceuticals in the transaction. Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Pfizer’s $25 Million Equity Investment in Zentalis Pharmaceuticals

Latham & Watkins represented Zentalis Pharmaceuticals in the transaction. Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Zentalis Pharmaceuticals’ $150.4 Million Common Stock Offering

Latham & Watkins LLP represented Zentalis Pharmaceuticals in the offering. Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here